Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Schizophrenia: full-pipeline trial registry
76 of 318 indexed Schizophrenia trials are currently recruiting.
Corpus placement: #23 of 28,707 conditions by registered trial count.
318 US clinical trials · 76 currently recruiting · #23 of 28,707 conditions by registered trial count
Schizophrenia: 318 US clinical trials tracked, 76 recruiting.
Schizophrenia is the subject of 318 registered US clinical trials on ClinicalTrials.gov, 76 of them currently open to new participants. 90 are in Phase 3-4 (later-stage) and 87 in Phase 1-2 (earlier-stage). The most active sponsor is University of Maryland, Baltimore, running 14 of these trials.
Enrollment posture brief
Registry condition schizophrenia
OPEN 76 | RECR 24% | LATE 90 | EARLY 87 | RANK #23 | SPON 14
Volume-matched condition peers
Nearest open-share peer: Dehydration (24% recruiting · 21 trials)
Schizophrenia lists 76 open slots (24% of 318 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Schizophrenia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Schizophrenia is recruiting below its size-band peers.
76 of 318 indexed trials (23.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Schizophrenia trials is spread across many organizations.
University of Maryland, Baltimore accounts for 14 of 318 trials (4.4%). 129 distinct sponsors appear on at least one study for this condition label.
-
Typical Schizophrenia enrolment sits around 83 participants.
Median target enrolment is 83 among the 316 trials that report a genuine target (sentinel values excluded). 169 of those (53.5%) plan for fewer than 100 participants.
-
Schizophrenia research is mostly interventional.
290 interventional and 28 observational studies make up this index (91.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
318 total, page 4 of 7
Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
Otsuka Pharmaceutical Development & Commercialization
NCT01423916
Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
Northwell Health
NCT00320671
A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia
Karuna Therapeutics
NCT03697252
Clinical Study Of Schizophrenia in Both Men and Women
GlaxoSmithKline
NCT00071747
Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness
Dartmouth-Hitchcock Medical Center
NCT02421965
Virtual Reality Job Interview Training in Severe Mental Illness
University of Michigan
NCT03049813
Biomarkers in First Episode Schizophrenia
NYU Langone Health
NCT02033382
Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia
Pfizer
NCT00580125
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
Takeda
NCT02477020
Determining Metabolic Effects of Valproate and Antipsychotic Therapy
Washington University School of Medicine
NCT00167934
Dopamine Function and Reward Processing In Schizophrenia
National Institute on Drug Abuse (NIDA)
NCT01035996
Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia
Cerevel Therapeutics
NCT05245539
Work Activity Augmented by Cognitive Rehabilitation for Schizophrenia
VA Office of Research and Development
NCT00430560
A New Paradigm for Illness Monitoring and Relapse Prevention in Schizophrenia
Dartmouth-Hitchcock Medical Center
NCT01952041
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
Avanir Pharmaceuticals
NCT02477670
Safety and Tolerability of Risperidone Implants
Braeburn Pharmaceuticals
NCT02773576
The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders
NYU Langone Health
NCT03166098
High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms
Donald C. Goff, MD
NCT00403546
Treatment for First-Episode Schizophrenia
Northwell Health
NCT00000374
Contingency Management of Alcohol Abuse in the Severely Mentally ILL
University of Washington
NCT01567943
Personalized and Scalable Cognitive Remediation Approaches
New York State Psychiatric Institute
NCT01945333
Cognitive-Behavioral Therapy in Veterans With Schizophrenia
VA Office of Research and Development
NCT00688259
Risk Perception in Drug-Dependent Adults With and Without Schizophrenia
National Institute on Drug Abuse (NIDA)
NCT01031563
Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI
Dartmouth-Hitchcock Medical Center
NCT02334280
Attention Shaping Procedures for Improving Psychosocial Skills Among Adults With Schizophrenia
University of Medicine and Dentistry of New Jersey
NCT00391677
Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.
Wyeth is now a wholly owned subsidiary of Pfizer
NCT00380224
Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder
H. Lundbeck A/S
NCT02901587
Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study
Neurocrine Biosciences
NCT02748694
Family Intervention for Mental Illness and Substance Abuse
Dartmouth-Hitchcock Medical Center
NCT00043693
Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia
Eli Lilly and Company
NCT00051298
A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia (MK-8189-019)
Merck Sharp & Dohme
NCT05893862
A Study of Strategies to Improve Schizophrenia Treatment
US Department of Veterans Affairs
NCT00156637
Improving Negative Symptoms & Community Engagement in Veterans With Schizophrenia
VA Office of Research and Development
NCT02469389
D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
Yale University
NCT00237809
Study of CAD-9303 in Subjects With Schizophrenia
Cadent Therapeutics
NCT04306146
High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia
Northwestern University
NCT01569659
A Self-Management Program for Adults With Both Schizophrenia and a Co-occurring Medical Condition
University of Maryland, Baltimore
NCT00525304
Imaging of Brain Receptors in Healthy Volunteers and in Patients With Schizophrenia
National Institute of Mental Health (NIMH)
NCT00061789
Nicotinic Receptors and Schizophrenia
University of Colorado, Denver
NCT01400477
Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia
H. Lundbeck A/S
NCT02202226
Naltrexone Treatment of Alcohol Abuse in Schizophrenia
State University of New York - Upstate Medical University
NCT00145847
A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia
Alkermes
NCT01493726
Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects
University of Michigan
NCT00815854
Mobile Self-Tracking of Mental Health
VA Office of Research and Development
NCT05023252
Effectiveness of a Lifestyle Intervention for Increasing Physical Activity in Adults With Schizophrenia
Veterans Medical Research Foundation
NCT00338832
Luteolin for the Treatment of People With Schizophrenia
University of Maryland, Baltimore
NCT05204407
Oxytocin and CBSST for People With Schizophrenia
University of Maryland, Baltimore
NCT01752712
Comparative Bioavailability of Risperidone
Rovi Pharmaceuticals Laboratories
NCT03527186
Comparative Bioavailability of Risperidone.
Rovi Pharmaceuticals Laboratories
NCT05179525
Effects of Motivating People With Schizophrenia to Exercise
The University of Tennessee, Knoxville
NCT00559572
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 47 |
| Phase 2 | 40 |
| Phase 3 | 50 |
| Phase 4 | 40 |
Top Sponsors
Named interventions
Most-linked intervention names on Schizophrenia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Schizophrenia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Schizophrenia page
318 registered trials, 76 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 76 Schizophrenia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Maryland, Baltimore sponsors the most Schizophrenia trials on record, review their full trial history before evaluating a specific study. See University of Maryland, Baltimore's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Schizophrenia condition card totals 318 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.